Twice-yearly injectable lenacapavir, an HIV-prevention drug, reduces risk by 96%
Gilead researchers say lenacapavir “has the potential to be one of the most impactful interventions” in the battle against HIV.
September 13, 2024
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Gilead researchers say lenacapavir “has the potential to be one of the most impactful interventions” in the battle against HIV.
The availability of a generic version likely means a lower cost of PrEP.
Pre-exposure prophylaxis is a generic term — it applies to things like malaria drugs and such — but for HIV it's synonymous with Truvada. Turns out, it shouldn't be.
Federal health officials indicated a shift in the ongoing fight against HIV and AIDS when the CDC announced Wednesday new clinical guidelines that encourage the use of pre-exposure prophylaxis, or PrEP.
The anniversary of PrEP's approval by the FDA ought to be remembered for how much has changed, and the potential for even greater change, says the CEO of Scruff.
How a party prompted a man to evaluate his health — and how others talk about HIV.
Despite the green light from the CDC and WHO, the stigma against using HIV prevention medication continues in both the LGBT and medical communities.
The congresswoman asked why the HIV prevention drug costs nearly $2,000 in the U.S. but only $8 in Australia.
The donation amounts to 2.4 million bottles each year -- but activists say it isn't enough.
The U.S. government, which developed and patented the use of Truvada for PrEP, got nothing.